Parsaclisib FDA Approval Status
FDA Approved: No
Generic name: parsaclisib
Company: Incyte
Treatment for: Non-Hodgkin's Lymphoma
Parsaclisib is a next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ) in development for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
Development timeline for parsaclisib
| Date | Article |
|---|---|
| Jan 25, 2022 | Incyte Provides Update on Parsaclisib and MCLA-145 |
| Nov 1, 2021 | Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
